



## MEDICAL TIPS

### K-GLIM-M TABLETS

Issue X, No. 39, 2022

#### **Clinical Utility of Glimepiride and Metformin Fixed-Dose Combination in Obese/Overweight Patients with Type 2 Diabetes Mellitus in Indian Settings**

*Sinha B et al. Chronicles of Diabetes Research & Practice 2022; 1(2): 58-68.*

- In India, glimepiride has become a promising option for add-on therapy with metformin in patients with T2DM due to its efficacy, safety and cost-effectiveness.
- This study aimed to analyse the clinical utility of multiple strengths of glimepiride and metformin fixed-dose combination (FDC) in obese/overweight patients with T2DM.
- Overall data of 1345 obese and overweight patients taking multiple strengths of glimepiride and metformin fixed dose combination (2mg glimepiride and 500/850/1000 mg metformin FDC) was analysed using a case based questionnaire survey.
- A majority of the patients observed no weight gain, optimum levels of blood pressure and a significant reduction in HbA1c, FPG and PPG on treatment with glimepiride and metformin FDC.

**The real-world evidence in the Indian clinical setting indicates that the glimepiride and metformin FDC was found to be effective in achieving glycaemic control and it is observed to be safer in terms of weight gain and hypoglycaemia.**

